This book provides a comprehensive guide to the major issues surrounding the development of anxiolytic drugs. Written by authors well known for their extensive experience in the field of drug development, this book will be of interest to the academic community frequently involved in clinical trials of potential anxiolytic compounds, as well as to the pharmaceutical industry in the formulation of drug development programs.

This work provides information on developing novel anxiolytics. Recommendations for developing anxiolytic compounds are included based on the experience of the authors. Numerous compounds are in the precli nical pipeline and the pharmaceutical industry, as well as anyone interested in the design and conduct of schizophrenia clinical trials, are waiting for these research results.

The interest in developing novel antipsychotics is especially keen at this time and this book presents the latest information in that development. Numerous compounds are in the preclinical and clinical pipeline. The pharmaceutical industry, as well as psychiatrists, clinicians, mental health professionals and anyone else interested in the design and conduct of clinical trials of schizophrenia, are waiting for these research results. Revealing recommendations for developing antipsychotic compounds based on the extensive experience of the authors, this work will provide long?awaited information on a previously unexplored area.